An easier time for restricted mobility in HCM patients?

Published Date: 13 Mar 2023

Electrophysiologist John Mandrola, MD. and Rachel Lampert, MD, reviewed the LIVE-HCM study comparing exercise and no exercise in people with hypertrophic cardiomyopathy.

Read Full News

Latest News

Buridan’s Ass and the Limits of Medical Reasoning

Not every clinical dilemma has a rational answer, and pretending otherwise carries its own risks.

9/11-Related Cancers Still Emerging 25 Years Later

Cancer diagnoses among people exposed to the World Trade Center disaster continue to be reported 25 years after 9/11, highlighting the long latency of some WTC-related malignancies.

AI Tool Shows Promise for Lung Cancer Response Assessment

An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

FDA OKs First Drug to Target Muscle Loss in SMA

Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.

Admin Hurdles, Not Insurance, Block Bariatric Surgery Access

Secret shopper calls to bariatric programs in two US states find that administrative and scheduling barriers — not insurance — may limit access to initial appointments.

Acute Otitis Media: The Cost of a Common Childhood Infection

Dr. Pichichero discusses the financial and health costs of acute otitis media.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Latest News

Not every clinical dilemma has a rational answer, and pretending otherwise carries its own risks.

Cancer diagnoses among people exposed to the World Trade Center disaster continue to be reported 25 years after 9/11, highlighting the long latency of some WTC-related malignancies.

An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.

Secret shopper calls to bariatric programs in two US states find that administrative and scheduling barriers — not insurance — may limit access to initial appointments.

Dr. Pichichero discusses the financial and health costs of acute otitis media.

News All Time

Disparities in Urban and Rural Mortality from Non-Melanoma Skin Cancers

This study assessed differences in age-adjusted mortality rates in nonmelanoma skin cancer in U.S. urban and rural populations.

Improving Resident Attitudes Toward Patients with SCA

This study evaluated whether a CAB-designed educational intervention could improve resident physician attitudes toward patients with SCA.

Does This New Clue Explain the Smoking-Parkinson’s Mystery?

Carbon monoxide may help explain the long-observed but perplexing association between smoking and a lower risk for Parkinson’s disease.

Cancer Screening Lower for Adults With Disabilities

A new study finds millions of adults with disabilities are missing critical cancer screenings, but those with disabilities have higher rates of at-home stool testing for colorectal cancer.

Early Remdesivir May Protect Kidney Grafts After COVID

Early antiviral intervention is associated with lower risks for graft loss and cardiovascular events in kidney transplant recipients with COVID.

The Future of Oncology Clinical Pathways in VHA

VA oncology Clinical Pathways logged 26,613 entries for 11,835 patients in FY25, standardizing care and paving the way to Oracle Health EHR.

Normal, but Not Optimal: Rethinking Perimenopause

In this roundtable, Drs Rachel Rubin, Makeba Williams, and Anna Cabeca discuss the changing landscape of perimenopause care — and why every clinician should join the conversation.

Inflammation on Imaging May Help Predict Hand OA Progression

Synovitis detected using ultrasonography and MRI is associated with increased odds of structural worsening in thumb base and finger joints in patients with hand osteoarthritis.

Allo-HSCT Shows Long-Term Benefit in Hepatosplenic Lymphoma

Researchers examine the roles of allogeneic and autologous HSCT in patients with hepatosplenic T-cell lymphoma and identify factors linked to survival after transplantation.

Insomnia Diagnoses, Rx Surge in Catalan Primary Care

Insomnia diagnoses and related pharmacologic prescriptions show a rise among adults in Central Catalonia; those with insomnia and polypharmacy are more likely to receive pharmacologic treatment.

Cenobamate May Offer Benefits in Rare Childhood Epilepsy

Cenobamate is linked to sustained seizure control and higher treatment retention rates over 12 months in children with developmental and epileptic encephalopathies.

Can Antiviral PEP Protect Workers During Ebola Outbreaks?

Rapid delivery of antiviral post-exposure prophylaxis at high coverage could substantially reduce deaths among healthcare workers during orthoebolavirus outbreaks, a modeling study suggests.

SMC Extends SMA Drug Access to Newborns

The Scottish Medicines Consortium extends nusinersen access to pre-symptomatic 5q SMA infants after trial data showed most learned to walk.

Vaccines Worked for Decades: Why Are Diseases Returning?

Measles, diphtheria, and polio are reappearing in places where vaccination once kept them at bay, raising concerns about declining coverage and immunity gaps.

Low-Dose Sq Decitabine ± Venetoclax in Myeloid Malignancies

Across 4 VA sites, 22 veterans with AML, MDS, or CMML tolerated low-dose sq decitabine±venetoclax, showing feasibility in a hard-to-treat population.

A Novel Virtual Culinary Program for Veterans With Cancer

A single virtual cooking class helped veterans in oncology care manage appetite loss and weight change, with 9.3/10 satisfaction in this VA pilot.

Recommended News For You

Smart exercise planning could boost recovery for people with cancer

According to research, hospitals can save money and help cancer patients by implementing a basic intervention.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer

GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.

For relapsed or resistant DLBCL, odronextamab produced positive results.

Decoding calcifications in breast cancer: Towards personalized medicine

Recommended Articles For You

Engineering the Future of Oncology with CAR- Natural Killer Cell Design & Therapeutics 

Targeting BRAF V600E in mCRC: FOLFOX, Cetuximab & Encorafenib Strategies 

Mast Cell-Tumor Cell Interactions in OSCC: Genetic and microRNA Insights 

Unlocking the Mystery of Ovarian Cancer Staging 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation

2.

Cancer during young adulthood carries long-term mental toll, study finds

3.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

4.

Massachusetts nurses with brain tumors: Department of Public Health 'in communication' with Newton-Wellesley

5.

Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar

1.

Navigating the Stages of Thyroid Cancer: A Guide for Patients

2.

Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options 

3.

The Science Behind Thrombolytic Drugs and Their Benefits 

4.

Clinical Pharmacology of Hypoxia-Activated Anticancer Prodrugs

5.

Does Lactate Signal Anemia? Exploring the Complexities of Hyperlactatemia and Red Blood Cell Health

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

2.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Blood Clotting Disorders Explained

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot